Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. - Concepedia

Concepedia

Publication | Closed Access

Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.

104

Citations

35

References

2002

Year

William D. Fox, Brian Higgins, Krista Maiese, Marija Drobnjak, Carlos Cordon‐Cardo, Howard I. Scher, David B. Agus

Abstract

rhu alpha VEGF has cytostatic clinical activity in this androgen-independent prostate cancer xenograft model, and the addition of paclitaxel demonstrates increased clinical activity.

References

	Year	Citations
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo K. Jin Kim, Bing Li, Jane Winer, Nature Tumor BiologyAngiogenesisTumour GrowthEndothelial DysfunctionPathology	1993	3.6K
Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma Noel Weidner, J Folkman, F. Pozza, JNCI Journal of the National Cancer Institute	1992	1.8K
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Noel Weidner, Peter R. Carroll, Jonathan Flax, PubMed	1993	1.6K
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Leonard G. Presta, H Chen, Shane J. O'Connor, PubMed AngiogenesisSolid TumorsMumab VegfTumor GrowthMedicine	1997	1.6K
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Mark D. Pegram, A. Lipton, Daniel F. Hayes, Journal of Clinical Oncology	1998	1.1K
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Alicia M. Viloria Petit, Janusz Rak, Mien‐Chie Hung, PubMed	1997	841
Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data Kim Margolin, Michael Gordon, Eric Holmgren, Journal of Clinical Oncology	2001	366
The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Christopher J. Sweeney, Kathy D. Miller, Sean E. Sissons, PubMed Antiangiogenic PropertyImmunologyDocetaxel TreatmentPharmacotherapyAngiogenesis	2001	333
Comparison of microscopic vascularity in benign and malignant prostate tissue Steven A. Bigler, Robert E. Deering, Michael K. Brawer Human Pathology UrologyVascular ImageMedicineSurgical PathologyHistopathology	1993	325
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Dong M. Shin, Nicholas J. Donato, Román Pérez-Soler, PubMed Neck CancerImmunologyPathologyDermatologyTumor Biology	2001	299

Page 1